HOME >> BIOLOGY >> NEWS
Interim analysis of anti-cancer vaccine, BiovaxID, to be conducted

Tampa, FL--June 13, 2007 -- Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announces a milestone in its effort to gain accelerated conditional approval for BiovaxID. The independent Data Monitoring Committee (DMC) has requested an interim analysis of all primary and secondary endpoints. The DMC is the independent committee that is responsible for safety and efficacy reviews of the BiovaxID Phase 3 Clinical Trial. Further, the DMC has requested data lock to occur in September 2007 to facilitate this interim analysis.

Additionally, the DMC has informed the Company that, after its review of unblinded data for the BiovaxID Phase 3 Clinical Trial, there are no identifiable safety concerns related to this therapy. The company believes that BiovaxIDs strong safety record will be supportive of its planned application for accelerated conditional approval of BiovaxID.

BiovaxID is an anti-cancer vaccine that is in pivotal Phase 3 Clinical Trial for the indication of non-Hodgkins lymphoma (NHL). BiovaxID is a personalized, patient specific vaccine designed to stimulate the patients own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating NHL, BiovaxID is designed to kill only cancerous B-cells. The BiovaxID Phase 3 clinical trial is being conducted at fourteen oncology centers within the United States and nineteen centers in Russia.

The Chairman of the DMC, Dr. Gerry Messerschmidt, MD, FACP, stated, There are no identifiable safety concerns in the current BiovaxID Phase 3 pivotal Clinical Trial at this time in our data review. To facilitate Biovests regulatory agency discussions and petitions based on its announced decision to seek accelerated conditional approval of BiovaxID, the DMC has requested that the database be fully updated and a
'"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
13-Jun-2007


Page: 1 2 3

Related biology news :

1. Interim Aranesp data suggest major response in anemic patients with MDS
2. Interim long-term follow-up data show AMG 531 increases platelets in patients with ITP
3. Interim data suggest major response with Aranesp(R) in anemic patients with MDS
4. AAAS analysis finds Congress would add billions to FY 2008 R&D investment
5. Genetic analysis finds greater threat in frog-killing fungus
6. Genomic analysis uncovers new targets for HIV vaccine
7. Manchester University helps with pharaoh DNA analysis
8. UN issues analysis of global investors sustainable energy gold rush
9. New NIST reference material for peptide analysis
10. New system for soil analysis
11. DNA analysis suggests under-reported kills of threatened whales

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/19/2020)... ... ... The director of stem cell biotechnology company Asymmetrex , Dr. James L. ... have easier access to stem cell counting, they will soon make it a routine ... weekend in the U.S., Asymmetrex is offering free tissue stem cell counting at its ...
(Date:6/13/2020)... , ... June 11, 2020 , ... ... services, announces a significant expansion of its forensic genealogy team. Bode’s Forensic ... attorneys through proven forensic genealogy and DNA analysis methods. The team has added ...
(Date:6/5/2020)... ... June 04, 2020 , ... Murrieta Genomics has ... patent application for simplified sample preparation for Next Generation Genomic Sequencing (NGS) . ... cost, time, and complexity of sample preparation. , “I have been at the bench ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 08, 2020 , ... ... a significant expansion of laboratory operations through its COVID-19 testing service, Bode-CARES ... programs. , Bode-CARES provides a turnkey solution that includes a ...
(Date:7/7/2020)... ... 06, 2020 , ... R3 International is now offering stem cell therapy for ... cells. Depending on the patient's condition, treatment may be offered IV, intrathecal or with ... form of Alzheimers dementia, and the incidence continues to increase as individuals live longer. ...
(Date:7/1/2020)... , ... June 30, 2020 ... ... tissue data insights, today announced that the launch of a new ... with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a ...
(Date:6/28/2020)... ... June 26, 2020 , ... The ... providers, today announced its strong opposition to the recently introduced bicameral Facial ... blanket ban on most federal use of nearly all biometric and related image ...
Breaking Biology Technology:
Cached News: